Properties (62)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:activities |
promising results in animal models
|
| gptkbp:advertising |
targeted oncology market
|
| gptkbp:affiliatedWith |
gptkb:ABC_Research_Lab
|
| gptkbp:built |
formulation stability
|
| gptkbp:campusFacilities |
gptkb:XYZ_University
|
| gptkbp:chemicalFormula |
mass spectrometry
sulfonamide lipophilic C20H24N2O2S interacts with DNA contains thiophene ring stable under standard conditions |
| gptkbp:clinicalTrials |
high potential
not yet in clinical trials potential for targeted therapy |
| gptkbp:collaborations |
international collaboration
pharmaceutical company |
| gptkbp:compatibleWith |
inhibitor
|
| gptkbp:competitors |
high
WME-678,_WME-679 |
| gptkbp:composedOf |
multi-step synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:environmentalImpact |
low toxicity in preliminary tests
|
| gptkbp:formulation |
oral administration
|
| gptkbp:funding |
government grant
|
| gptkbp:future_plans |
5 years
preclinical |
| https://www.w3.org/2000/01/rdf-schema#label |
WME-677
|
| gptkbp:impact |
none reported in studies
|
| gptkbp:inventiveStep |
effective against cancer cell lines
|
| gptkbp:isATypeOf |
1234567-89-0
|
| gptkbp:judgingCriteria |
selective for cancer cells
|
| gptkbp:notableWork |
significant
|
| gptkbp:origin |
N-(4-(4-(dimethylamino)phenyl)-6-methylpyrimidin-2-yl)-N-(2-methylphenyl)thiophene-2-sulfonamide
|
| gptkbp:patentAssignee |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:patentCitation |
US1234567B2
|
| gptkbp:patentStatus |
pending
|
| gptkbp:publications |
Journal of Medicinal Chemistry
|
| gptkbp:regulatoryBody |
high
|
| gptkbp:regulatoryCompliance |
not approved
|
| gptkbp:related_to |
WME-678
|
| gptkbp:releaseYear |
2020
|
| gptkbp:research_areas |
oncology
cancer treatment |
| gptkbp:research_focus |
develop effective cancer treatment
novel anti-cancer therapies |
| gptkbp:researchAndDevelopment |
positive results
|
| gptkbp:route |
oral
|
| gptkbp:safety_features |
under evaluation
|
| gptkbp:safetyFeatures |
ongoing
completed |
| gptkbp:targets |
gptkb:EGFR
human MAPK pathway cancer cells protein kinase |
| gptkbp:team |
Dr._Smith's_team
|
| gptkbp:technology |
clinical trials planned
|
| gptkbp:triggerType |
inhibits cell proliferation
|
| gptkbp:uses |
potential anti-cancer agent
|
| gptkbp:weight |
356.49 g/mol
|